SCN1A IVS5N+5 polymorphism and response to sodium valproate: A multicenter study

Pharmacogenomics

Volumn 13, Issue 13, 2012, Pages 1477-1485

  Haerian, Batoul Sadat ^a   Baum, Larry ^b   Tan, Hui Jan ^c   Kwan, Patrick ^d   Raymond, Azman Ali ^c   Saruwatari, Junji ^e   Nakagawa, Kazuko ^e   Mohamed, Zahurin ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e KUMAMOTO UNIVERSITY   (Japan)

Author keywords

alternative splicing; epilepsy; meta analysis; polymorphism; SCN1A; sodium valproate

Indexed keywords

GENOMIC DNA; SODIUM CHANNEL NAV1.1; VALPROIC ACID;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; CHINESE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENERALIZED EPILEPSY; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALAYSIAN; MALE; META ANALYSIS; MULTICENTER STUDY; PRESCHOOL CHILD; RACE DIFFERENCE; SCHOOL CHILD; SCN1A GENE;

ADOLESCENT; ADULT; ALTERNATIVE SPLICING; ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; COHORT STUDIES; EPILEPSY; EPILEPSY, GENERALIZED; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HONG KONG; HUMANS; MALAYSIA; MALE; MIDDLE AGED; MODELS, GENETIC; NAV1.1 VOLTAGE-GATED SODIUM CHANNEL; POLYMORPHISM, GENETIC; VALPROIC ACID; YOUNG ADULT;

EID: 84867507152     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.127     Document Type: Article

References (29)

1. Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N. Engl. J. Med. 365, 919-926 (2011)
2. Löscher W. Mechanisms of drug resistance. Epileptic Disord. 7(Suppl. 1), S3-S9 (2005).
3. Laso? W, Dudra-Jastrz?bska M, Rejdak K, et al. Basic mechanisms of antiepileptic drugs and their pharmacokinetic/pharmacodynamic interactions: an update. Pharmacol. Rep. 63, 271-292 (2011).
4. Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?. Cell. Mol. Life Sci. 64, 2090-2103 (2007)
5. Chateauvieux S, Morceau F, Dicato M, et al. Molecular and therapeutic potential and toxicity of valproic acid. J. Biomed. Biotechnol. pii, 479364
6. Catterall WA. Voltage-gated sodium channels at 60: structure, function, and pathophysiology. J. Physiol. 1, 2577-2589 (2012)
7. Osaka H, Ogiwara I, Mazaki E, et al. Patients with a sodium channel a 1 gene mutation show wide phenotypic variation. Epilepsy Res. 75, 46-51 (2007)
8. Catterall WA, Kalume F, Oakley JC. Ion channel voltage sensors: structure, function, and pathophysiology. Neuron 67, 915-928 (2010)
9. Payandeh J, Scheuer T, Zheng N, et al. The crystal structure of a voltage-gated sodium channel. Nature 475, 353-358 (2007)
10. Mantegazza M, Curia G, Biagini G, et al. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol. 9, 413-424 (2010)
11. Zuliani V, Fantini M, Rivara M. Sodium channel blockers as therapeutic target for treating epilepsy: recent updates. Curr. Top Med. Chem. 12, 962-970 (2012)
12. Zhang W, Duan S, Bleibel WK, et al. Identification of common genetic variants that account for transcript isoform variation between human populations. Hum. Genet. 125, 81-93 (2009)
13. Copley RR. Evolutionary convergence of alternative splicing in ion channels. Trends Genet. 20, 171-176 (2004)
14. Tan J, Liu Z, Nomura Y, Goldin AL, et al. Alternative splicing of an insect sodium channel gene generates pharmacologically distinct sodium channels. J. Neurosci. 22, 5300-5309 (2002)
15. Fletcher EV, Kullmann DM, Schorge S. Alternative splicing modulates inactivation of type 1 voltage-gated sodium channels by toggling an amino acid in the first S3-S4 linker. J. Biol. Chem. 286, 36700-36708 (2011)
16. Tate SK, Depondt C, Sisodiya SM, et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc. Natl Acad. Sci. USA 102, 5507-5512 (2005)
17. Heinzen EL, Yoon W, Tate SK, et al. Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. Am. J. Hum. Genet. 80, 876-883 (2007)
18. Tate SK, Singh R, Hung CC, et al. A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet. Genomics 16, 721-726 (2006)
19. Krikova EV, Val'dman EA, Avakian GN, et al. Association study of the SCN1 gene polymorphism and effective dose of lamotrigine. Zh. Nevrol. Psikhiatr. Im. S S Korsakova 109, 57-62 (2009)
20. Zimprich F, Stogmann E, Bonelli S, et al. A functional polymorphism in the SCN1A gene is not associated with carbamazepine dosages in Austrian patients with epilepsy. Epilepsia 49, 1108-1109 (2008)
21. Abe T, Seo T, Ishitsu T, et al. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Br. J. Clin. Pharmacol. 66, 304-307 (2008)
22. Kwan P, Poon WS, Ng HK, et al. Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet. Genomics 18, 989-998 (2008)
23. Sánchez MB, Herranz JL, Leno C, et al. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy. Seizure 19, 93-101 (2010)
24. Manna I, Gambardella A, Bianchi A, et al. A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia 52, e40-e44 (2011)
25. Thompson CH, Kahlig KM, George AL Jr. SCN1A splice variants exhibit divergent sensitivity to commonly used antiepileptic drugs. Epilepsia 52, 1000-1009 (2011)
26. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 22, 489-501 (1981)
27. Panayiotopoulos CP. The new ILAE report on terminology and concepts for organization of epileptic seizures: a clinician's critical view and contribution. Epilepsia 52, 2155-2160 (2011)
28. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51, 1069-1077 (2009)
29. Bax L, Yu LM, Ikeda N, et al. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med. Res. Methodol. 6, 1-11 (2006).